Let’s break this shill post down:
?
❌ “It’s not hitting $1 unless LP does a reverse split”
False premise.
NWBO hitting $1 has nothing to do with a reverse split and everything to do with catalysts — namely MHRA approval, IFR access, NICE endorsement, and the unfolding of international trial and platform integration.
Reverse splits are cosmetic tools for uplisting, not organic price drivers. The implication that $1 is unreachable without one ignores:
• A fully validated MAA at MHRA
• NHS recognition on the High Cost Drugs list
• NICE already preparing an appraisal
• Proven OS data in peer-reviewed journals
If you’re ignoring those, you’re not analyzing — you’re distracting.
?
❌ “She is happy selling shares in the .20s”
That’s absurd.
NWBO’s financing has been strategic survival capital, not indiscriminate dumping. The company raised:
• At-market funding during periods of opportunity
• Non-toxic convertible deals (e.g., Yorkville) to retire debt without diluting at a deep discount
• And avoided death-spiral structures seen in failed biotechs
If Linda Powers wanted to cash out, she could have done so years ago — not after shepherding the company through Phase 3 completion, peer review, submission, and near-term regulatory inflection.
Saying she’s “happy” selling in the .20s ignores every piece of actual behavior.
?
❌ “.50 would be a victory at this point”
If DCVax-L is approved — and the market finally realizes it’s not just a product, but a platform with potential global reach — then .50 is not a victory, it’s a gross mispricing.
Let’s get real:
• $200K+ per patient treatment value
• Multiple jurisdictions warming up (UK, EU, IFR access confirmed)
• Platform potential across solid tumors
• Flaskworks automation for scaling
• Zero debt overhang
• Institutional-grade manufacturing in place
If this hits regulatory confirmation and trades at .50, that’s not a ceiling — it’s a launchpad for institutions and strategic acquirers to enter while retail gets shaken.
?
❌ “Market makers and hedge funds will short it again”
Only if there’s no real buying pressure.
But with approval, IFR access, NICE cost-effectiveness alignment, and global trial spillover (Murcidencel, Ennodc, Inserm, Fraunhofer)… this isn’t a weak rally — it’s a credibility cascade.
Shorting becomes exponentially riskier in a post-approval environment with real revenues or partnerships on deck.
?
🔥 Final Thought
This post is classic defeatist shill strategy:
• Pretend to be resigned to failure.
• Undermine morale.
• Paint every win as a trap.
• Ignore clinical, regulatory, and global footprint facts.
It’s fear dressed up as financial analysis. Don’t fall for it.
DCVax-L isn’t a penny stock gimmick. It’s a globally validated therapeutic on the cusp of recognition — and that makes posts like this all the more desperate.
I give this one five minutes before it disappears. The board’s run like a poker game where the dealer’s also holding the other player’s cards.
AI
